✨
AI Summary
- Sernova and Seraxis merge to form BetaNova, aiming for a functional cure for T1D.
- BetaNova combines Sernova's Cell Pouch with Seraxis' stem cell-derived islet cells.
- The goal is a cell therapy implant for people living with type 1 diabetes.
Guests on This Episode
JR
Jonathan Rigby
researcher · 2 podcast appearances
WP
Will Rust, Ph.D
1 podcast appearance